Study Shows Javelin Pharma's (JAV) DylojectTM is Well-Tolerated in High-Risk Patients
More News related to JAV
- Javelin Pharma (JAV) Posts Q3 Loss of 11c, Misses Views
- Javelin Pharmaceuticals, Inc. Reports Third Quarter 2009 Results
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Javelin Pharmaceuticals to Announce Third Quarter 2009 Financial Results
- Javelin Pharmaceuticals, Inc. Tops Up Balance Sheet Through Registered Direct Offering
Javelin Pharmaceuticals, Inc. (Amex: JAV) today reported encouraging findings from a new Phase I pharmacokinetic and safety study of Dyloject in patients with mild to moderate renal and mild hepatic impairment. Dyloject was well tolerated in these higher risk patient populations. The elimination rate of Dyloject's active ingredient diclofenac was statistically indistinguishable in all three patient groups compared with matched healthy controls. The Company plans to file a New Drug application for Dyloject in the United States during the fall of 2009, at the same dose used in these studies.
More from the release.
Related Categories
Corporate NewsStocks Mentioned
+0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
